MONTPELLIER, France, March 27, 2024--Regulatory News: MedinCell (Paris:MEDCL) has recently reached the commercial stage with the market launch by Teva of UZEDY™ for the treatment of schizophrenia. UZEDY is the first innovative product based on MedinCell’s long-acting injectable (LAI) BEPO® technology approved by US FDA.
MONTPELLIER, France, March 15, 2024--Regulatory News: MedinCell (Paris:MEDCL) has recently reached the commercial stage with the market launch by Teva of UZEDY™ for the treatment of schizophrenia. UZEDY is the first innovative product based on MedinCell’s long-acting injectable (LAI) BEPO® technology approved by US FDA.
MONTPELLIER, France, March 13, 2024--Regulatory News: MedinCell (Paris:MEDCL):